The Budget Impact Analysis of Nilotinib in the Second-Line Treatment of Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia
Sep 1, 2018, 00:00 AM
10.1016/j.jval.2018.07.728
https://www.valueinhealthjournal.com/article/S1098-3015(18)33085-7/fulltext
Section Title :
Section Order :
620
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33085-7&doi=10.1016/j.jval.2018.07.728